Total Payments
$31,605
2023 Payments
$150.34
Companies
11
Transactions
38
Medicare Patients
1,066
Medicare Billing
$69,205
Payment Breakdown by Category
Research$28,760 (91.0%)
Travel$1,791 (5.7%)
Food & Beverage$1,029 (3.3%)
Other$25.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $28,760 | 11 | 91.0% |
| Travel and Lodging | $1,791 | 8 | 5.7% |
| Food and Beverage | $1,029 | 18 | 3.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25.00 | 1 | 0.1% |
Payments by Type
Research
$28,760
11 transactions
General
$2,845
27 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $31,291 | 23 | $0 (2020) |
| Amgen Inc. | $88.07 | 4 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $39.38 | 2 | $0 (2022) |
| GlaxoSmithKline, LLC. | $38.80 | 2 | $0 (2023) |
| Teleflex LLC | $32.09 | 1 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $29.58 | 1 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $25.00 | 1 | $0 (2020) |
| PFIZER INC. | $22.80 | 1 | $0 (2022) |
| Philips Electronics North America Corporation | $14.38 | 1 | $0 (2022) |
| Corcept Therapeutics | $12.50 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $150.34 | 6 | Amgen Inc. ($62.67) |
| 2022 | $114.46 | 6 | Novartis Pharmaceuticals Corporation ($39.38) |
| 2021 | $12.80 | 1 | GlaxoSmithKline, LLC. ($12.80) |
| 2020 | $812.80 | 4 | Eli Lilly and Company ($787.80) |
| 2019 | $13,816 | 4 | Eli Lilly and Company ($13,805) |
| 2018 | $8,072 | 15 | Eli Lilly and Company ($8,072) |
| 2017 | $8,627 | 2 | Eli Lilly and Company ($8,627) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $29.58 | General |
| Category: Cardiovascular | ||||||
| 09/15/2023 | Teleflex LLC | VASCBAND (Device) | Food and Beverage | In-kind items and services | $32.09 | General |
| Category: Interventional Access | ||||||
| 06/06/2023 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: Bone Health | ||||||
| 04/06/2023 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: Bone Health | ||||||
| 03/23/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $26.00 | General |
| Category: RESPIRATORY | ||||||
| 03/01/2023 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Bone Health | ||||||
| 06/22/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/02/2022 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: Bone Health | ||||||
| 05/18/2022 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: Endocrinology | ||||||
| 04/26/2022 | PFIZER INC. | PREVNAR 20 (Biological) | Food and Beverage | In-kind items and services | $22.80 | General |
| Category: VACCINES | ||||||
| 04/15/2022 | Philips Electronics North America Corporation | (1750) HS HQ (Device) | Food and Beverage | Cash or cash equivalent | $14.38 | General |
| Category: Medical Device | ||||||
| 03/16/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $19.68 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/14/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $12.80 | General |
| Category: RESPIRATORY | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $142.50 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF THREE TIRZEPATIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES, INADEQUATELY CONTROLLED WITH DIET AND EXERCISE ALONE | ||||||
| 07/09/2020 | Eli Lilly and Company | — | — | In-kind items and services | $368.80 | Research |
| Study: A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | ||||||
| 07/09/2020 | Eli Lilly and Company | — | — | In-kind items and services | $276.50 | Research |
| Study: A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | ||||||
| 02/14/2020 | SANOFI-AVENTIS U.S. LLC | SOLIQUA 100/33 (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $25.00 | General |
| Category: Endocrinology | ||||||
| 08/16/2019 | Circassia Pharmaceuticals Inc | TUDORZA PRESSAIR (Drug) | Food and Beverage | In-kind items and services | $11.83 | General |
| Category: PULMONARYRESPIRATORY DISEASES | ||||||
| 01/16/2019 | Eli Lilly and Company | — | — | In-kind items and services | $75.60 | Research |
| Study: A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | ||||||
| 01/08/2019 | Eli Lilly and Company | TRULICITY (Drug) | — | Cash or cash equivalent | $6,536.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS • Category: Diabetes | ||||||
| 01/07/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $7,193.00 | Research |
| Study: A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | ||||||
| 12/28/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,050.00 | Research |
| Study: A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | ||||||
| 12/24/2018 | Eli Lilly and Company | TRULICITY (Drug) | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS • Category: Diabetes | ||||||
| 12/03/2018 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $20.00 | General |
| 11/19/2018 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $109.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $11,027 | 3 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3298176 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $8,424 | 1 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $8,319 | 3 |
| A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | Eli Lilly and Company | $368.80 | 1 |
| A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $276.50 | 1 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 18-WEEK TRIAL OF INVESTIGATIONAL DULAGLUTIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES ON METFORMIN MONOTHERAPY | Eli Lilly and Company | $202.88 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF THREE TIRZEPATIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES, INADEQUATELY CONTROLLED WITH DIET AND EXERCISE ALONE | Eli Lilly and Company | $142.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 11 | 20 | $5,160 | $1,206 |
| 2022 | 1 | 13 | 24 | $5,952 | $1,260 |
| 2021 | 2 | 38 | 63 | $17,928 | $3,952 |
| 2020 | 14 | 1,004 | 1,321 | $336,116 | $62,787 |
Total Patients
1,066
Total Services
1,428
Medicare Billing
$69,205
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 20 | $5,160 | $1,206 | 23.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 13 | 24 | $5,952 | $1,260 | 21.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 27 | $9,288 | $2,070 | 22.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 23 | 36 | $8,640 | $1,882 | 21.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 225 | 498 | $179,778 | $20,530 | 11.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 158 | 158 | $60,040 | $17,844 | 29.7% |
| 90662 | Vaccine for influenza for injection into muscle | Office | 2020 | 111 | 116 | $12,816 | $6,842 | 53.4% |
| G0444 | Annual depression screening, 15 minutes | Office | 2020 | 156 | 156 | $9,516 | $2,759 | 29.0% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2020 | 17 | 17 | $9,384 | $2,756 | 29.4% |
| 90670 | Pneumococcal vaccine for injection into muscle | Office | 2020 | 12 | 12 | $4,691 | $2,653 | 56.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 85 | 111 | $27,195 | $2,653 | 9.8% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2020 | 25 | 31 | $17,112 | $2,588 | 15.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 112 | 117 | $3,744 | $1,930 | 51.6% |
| 93224 | Heart rhythm tracing, analysis, and interpretation of 48-hour ekg | Office | 2020 | 20 | 20 | $6,140 | $850.90 | 13.9% |
| 77080 | Bone density measurement using dedicated x-ray machine | Office | 2020 | 12 | 12 | $1,992 | $458.08 | 23.0% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2020 | 19 | 19 | $1,140 | $336.93 | 29.6% |
| G0009 | Administration of pneumococcal vaccine | Office | 2020 | 19 | 19 | $608.00 | $310.91 | 51.1% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 33 | 35 | $1,960 | $274.08 | 14.0% |
About Dr. Michael Chen, M.D
Dr. Michael Chen, M.D is a Internal Medicine healthcare provider based in Stayton, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1619926011.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Chen, M.D has received a total of $31,605 in payments from pharmaceutical and medical device companies, with $150.34 received in 2023. These payments were reported across 38 transactions from 11 companies. The most common payment nature is "" ($28,760).
As a Medicare-enrolled provider, Chen has provided services to 1,066 Medicare beneficiaries, totaling 1,428 services with total Medicare billing of $69,205. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Stayton, OR
- Active Since 05/10/2006
- Last Updated 04/14/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1619926011
Products in Payments
- TRULICITY (Drug) $12,058
- EVENITY (Biological) $88.07
- ENTRESTO (Drug) $39.38
- TRELEGY ELLIPTA (Drug) $38.80
- VASCBAND (Device) $32.09
- CAMZYOS (Drug) $29.58
- SOLIQUA 100/33 (Biological) $25.00
- PREVNAR 20 (Biological) $22.80
- (1750) HS HQ (Device) $14.38
- Korlym (Drug) $12.50
- TUDORZA PRESSAIR (Drug) $11.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.